Atlas Trials

Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment

Clinical trial NCT06529796 · COMPLETED

Trial details

NCT number
NCT06529796
Sponsor
Vertex Pharmaceuticals Incorporated
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Focal Segmental Glomerulosclerosis (FSGS)
Start date
2024-08-02
Primary completion
2024-12-20
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.